Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment.
TACE
elderly patients
hepatocellular carcinoma
palliative treatment
sorafenib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
01 Feb 2022
01 Feb 2022
Historique:
received:
16
12
2021
revised:
20
01
2022
accepted:
27
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Palliative treatment of elderly patients with hepatocellular carcinoma (HCC) is often challenging due to comorbidities or frailty, and data about the outcome and overall survival (OS) in these patients are limited. This was a retrospective single centre study. Patients were grouped according to their age as young (<60 years; YP), intermediate (60-70 years; IP) or elderly (>70 years; EP). Administration of chemotherapy or transarterial chemoembolization (TACE) was defined as palliative treatment. Therapy-related adverse events (AE) were assessed via CTCAE 5.0. Out of 656 patients analyzed,
Identifiants
pubmed: 35159035
pii: cancers14030768
doi: 10.3390/cancers14030768
pmc: PMC8833746
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncologist. 2009 Mar;14(3):216-21
pubmed: 19270027
Clin Liver Dis. 2015 May;19(2):223-38
pubmed: 25921660
Am J Cancer Res. 2021 Oct 15;11(10):4711-4724
pubmed: 34765289
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238
pubmed: 33349658
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Korean J Gastroenterol. 2020 Mar 25;75(3):147-156
pubmed: 32209803
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Chirurg. 2013 Apr;84(4):291-5
pubmed: 23479275
J Hepatol. 2012 Apr;56(4):886-92
pubmed: 22173160
J Gerontol A Biol Sci Med Sci. 1997 Sep;52(5):M305-9
pubmed: 9310085
Oncology. 2014;87(6):330-41
pubmed: 25227534
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Gut. 2010 Mar;59(3):387-96
pubmed: 20207642
J Am Coll Surg. 2011 May;212(5):787-95
pubmed: 21435922
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
N Engl J Med. 1986 Aug 28;315(9):559-63
pubmed: 3736639
J Hepatol. 2016 Dec;65(6):1140-1147
pubmed: 27469901
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Dig Liver Dis. 2012 Sep;44(9):788-92
pubmed: 22579445
Medicine (Baltimore). 2014 Dec;93(28):e264
pubmed: 25526453
J Hepatol. 2014 Aug;61(2):318-24
pubmed: 24703956
J Clin Oncol. 2013 Apr 10;31(11):1464-70
pubmed: 23460711
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Liver Cancer. 2019 Nov;8(6):457-467
pubmed: 31799203
J Hepatol. 2017 Aug;67(2):302-309
pubmed: 28336466
Clin Gastroenterol Hepatol. 2020 Jan;18(1):242-248.e5
pubmed: 31042582
Chirurg. 2015 Jul;86(7):670-5
pubmed: 25234504
J Gastrointest Surg. 2009 Sep;13(9):1627-35
pubmed: 19506976
Am J Gastroenterol. 1999 Sep;94(9):2460-6
pubmed: 10484009
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Liver Cancer. 2015 Dec;4(4):253-62
pubmed: 26734579
J Cancer. 2013 Sep 14;4(8):635-43
pubmed: 24155775
J Gastrointest Surg. 2009 Apr;13(4):695-701
pubmed: 19050982
Hepatogastroenterology. 2003 Nov-Dec;50(54):2022-7
pubmed: 14696457
PLoS One. 2017 Sep 8;12(9):e0184160
pubmed: 28886106
Lancet. 2002 May 18;359(9319):1734-9
pubmed: 12049862
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Gastroenterology. 2007 Jun;132(7):2557-76
pubmed: 17570226
Hepatol Res. 2010 Oct;40(10):997-1005
pubmed: 20887335
Int J Cancer. 2020 Oct 1;147(7):1970-1978
pubmed: 32167170
Lancet Oncol. 2015 Jul;16(7):859-70
pubmed: 26095784
Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138
pubmed: 33338442
Am Surg. 2007 Jan;73(1):42-7
pubmed: 17249455
Cardiovasc Intervent Radiol. 2020 Jul;43(7):1015-1024
pubmed: 32236670
Anticancer Res. 2021 Dec;41(12):6211-6216
pubmed: 34848475
Cancer. 2009 Dec 1;115(23):5507-15
pubmed: 19701904
Hepatology. 2014 Nov;60(5):1767-75
pubmed: 24839253
J Clin Oncol. 2011 Jan 10;29(2):235-41
pubmed: 21135285